Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens.

Lan-Fang LiRan QiTian-Tian WeiLei FengXin ZhangQiao Liu

Published in: Risk management and healthcare policy (2024)

From the perspective of the Chinese healthcare system, atezolizumab emerges as a cost-effective choice for the first-line treatment of NSCLC patients ineligible for platinum-based chemotherapy.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
locally advanced
single cell
prognostic factors
peritoneal dialysis
squamous cell carcinoma
stem cells
radiation therapy
advanced non small cell lung cancer
bone marrow